Neumora Therapeutics (NMRA) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary

Key data and clinical updates

• Presented new phase I-B data for NMRA-511 in Alzheimer's agitation, showing strong clinical effects and favorable safety, with plans to test higher doses in 2026 and move to pivotal studies in 2027.

• NMRA-511 demonstrated robust efficacy, especially in patients with elevated anxiety, with effect sizes surpassing comparators and consistent results across multiple clinical scales.

• Safety profile remains favorable, with no significant concerns; a single hyponatremia SAE was deemed confounded and not mechanistically linked.

• Plans include a MAD extension cohort, transition to a QD extended-release formulation, and extension of IP protection to 2046.

• Competitive landscape includes other V1a antagonist programs, but NMRA-511 is positioned as highly differentiated.

Pipeline and program strategy

• NLRP3 inhibitor NMRA-215 is being advanced for obesity, with a focus on CNS penetration to drive weight loss and cardioprotective effects.

• Upcoming biomarker data will focus on demonstrating brain IC90 coverage and cardioprotective markers, with first-in-human studies expected in the first half of the year.

• Commercial strategy for NMRA-215 targets combination with GLP-1s and maintenance settings, with potential for monotherapy as physician comfort grows.

• Additional CNS-penetrant and peripherally restricted NLRP3 compounds are in development to address pricing and indication-specific needs.

Other pipeline updates and financials

• Two M4 PAM compounds (NMRA-861, NMRA-898) are in phase 1; a mid-year update will determine which advances to proof-of-concept, with decision criteria including CNS penetration and PK variability.

• KOASTAL 2 and 3 data for navacaprant are expected in Q2, with increased enrollment to maximize study power and quality.

• Current cash position supports operations into Q3 2027, covering all major upcoming catalysts.